What's Happening?
SGS, a leading global testing, inspection, and certification company, has acquired CMIC, INC., a bioanalytical testing service provider based in Chicago, Illinois. This acquisition aims to bolster SGS's capabilities in supporting North American pharmaceutical
and biotech manufacturers. CMIC, INC. operates a 27,000 square foot GLP-compliant facility that provides bioanalysis across pre-clinical and clinical phases of drug development. The acquisition aligns with SGS's Strategy 27 objective to double North American sales by 2027, responding to increased regulation and demand for high-precision bioanalytical testing services.
Why It's Important?
The acquisition of CMIC, INC. by SGS is significant as it enhances SGS's ability to support the growing demand for bioanalytical testing services in North America, particularly in the pharmaceutical and biotechnology sectors. This move is expected to improve the efficiency and quality of drug development processes, ensuring compliance with stringent regulatory standards. The expansion of SGS's capabilities is likely to benefit pharmaceutical companies by providing them with reliable data to demonstrate the safety and efficacy of complex therapies, ultimately accelerating the availability of innovative treatments to patients.
